Myelofibrosis involving lymph node: a novel cytogenetic abnormality in a mimicker of mesenchymal neoplasm

A case of primary myelofibrosis involving lymph node and with a novel cytogenetic abnormality [del (18) (p11.2-3)] is reported. The abnormalities are identical among specimens from the lymph node, peripheral blood, and bone marrow that were analyzed years apart. Additionally, we show that the infiltrate by dysplastic megakaryocytes in the lymph node morphologically mimics a metastatic mesenchymal neoplasm, even when the clinical history myelofibrosis was known

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases. Keywords: T cells, Immunotherapy, Acute myeloid leukemia, Mixed phenotype acute leukemia, Chimeric antigen receptor

HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS CASE PRESENTATION

Purpose: The purpose of this article is to discuss a case presentation of a rare form of acquired Hemophagocytic Lymphohistiocytosis (HLH) and review the standard of care in addition to current therapeutic options for the disease. Method: A PubMed literature search conducted with search terms hemophagocytic lymphohistiocytosis, guidelines, survival, treatment, and EBV, allowed for the review and reference to nine applicable sources for this case presentation. Results: Increased observation of young adults with relapsed or refractory secondary HLH is needed to evaluate for remission with a new monoclonal antibody (mAb) therapy versus standard of care chemotherapeutic protocols with stem cell transplant. Conclusion: The patient is currently under active surveillance for relapse and possible treatment with emapalumab for secondary HLH to determine if remission-cure can be achieved. Emapalumab is a monoclonal antibody recently approved to treat relapsed and refractory sHLH